Bio Solution바이오솔루션
086820 · KOSDAQ · ₩086820 · 바이오솔루션
₩5,650▲ ₩60 (1.07%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩15B | ₩13B | ₩12B | ₩10B | ₩12B |
| Cost of sales | ₩5.6B | ₩4.7B | ₩4.3B | ₩4.2B | ₩4.2B |
| Gross profit | ₩9.6B | ₩8.2B | ₩8.1B | ₩5.9B | ₩7.6B |
| Operating income | −₩4.3B | −₩5.1B | −₩5B | −₩5.3B | −₩1.6B |
| Net income | ₩273M | −₩12B | −₩1.2B | −₩8.1B | −₩1.7B |
| Net income to shareholders | ₩273M | −₩12B | −₩1.2B | −₩8.1B | −₩1.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩68B | ₩67B | ₩92B | ₩92B | ₩94B |
| Current assets | ₩19B | ₩21B | ₩44B | ₩79B | ₩87B |
| Cash and equivalents | ₩12B | ₩13B | ₩5.5B | ₩13B | ₩29B |
| Total liabilities | ₩36B | ₩36B | ₩50B | ₩48B | ₩49B |
| Current liabilities | ₩34B | ₩33B | ₩47B | ₩46B | ₩49B |
| Borrowings | ₩29B | ₩26B | ₩34B | ₩31B | ₩28B |
| Total equity | ₩32B | ₩31B | ₩42B | ₩44B | ₩45B |
| Shareholders' equity | ₩32B | ₩31B | ₩42B | ₩44B | ₩45B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩1.3B | −₩2.3B | ₩2.2B | −₩3.8B | ₩83M |
| Capital spending | ₩185M | ₩380M | ₩1B | ₩3.6B | ₩388M |
| Free cash flow | −₩1.5B | −₩2.7B | ₩1.1B | −₩7.4B | −₩305M |
Consolidated where available. Amounts in won.
Also known as: Bio Solution / 바이오솔루션 / 086820 / KRX:086820
Source: KRX statistical information